BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37763107)

  • 1. Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.
    Sganga S; Riondino S; Iannantuono GM; Rosenfeld R; Roselli M; Torino F
    J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences.
    Barreca M; Lang N; Tarantelli C; Spriano F; Barraja P; Bertoni F
    Explor Target Antitumor Ther; 2022; 3(6):763-794. PubMed ID: 36654819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.
    Takakura T; Shimizu T; Yamamoto N
    Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38704241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugates: The Last Decade.
    Joubert N; Beck A; Dumontet C; Denevault-Sabourin C
    Pharmaceuticals (Basel); 2020 Sep; 13(9):. PubMed ID: 32937862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction to Antibody-Drug Conjugates.
    Pettinato MC
    Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
    Singh D; Dheer D; Samykutty A; Shankar R
    J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
    Nathan P; Rajeh A; Noor M; Boldt G; Fernandes R
    Curr Oncol; 2024 Apr; 31(4):2316-2327. PubMed ID: 38668075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
    Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
    Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers.
    Esapa B; Jiang J; Cheung A; Chenoweth A; Thurston DE; Karagiannis SN
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
    Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
    Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.
    Riccardi F; Dal Bo M; Macor P; Toffoli G
    Front Pharmacol; 2023; 14():1274088. PubMed ID: 37790810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of antibody-drug conjugates (ADCs) for cancer therapy.
    Marei HE; Cenciarelli C; Hasan A
    Cancer Cell Int; 2022 Aug; 22(1):255. PubMed ID: 35964048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.